ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$34.93
+1.51%Margins
Gross margin
81.2%
EBITDA margin
-3735.2%
EBIT margin
—
Net margin
-3534.9%
FCF margin
—
-6.3%
Return on equity
-5.0%
Return on assets
-31.5%
Return on invested capital
0.00x
Asset turnover
-$809.4M
Cash from operations
$5.32
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026